DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers.

​DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers. 

​